LuciRibo — Ribociclib 200 mg, 21 pcs, Lucius

LuciRibo — Ribociclib Tablets 200 mg, 21 Tablets

Product code: 515

9834₴ 10728₴ -8% On order · from 10 days

Analogues

1
Active ingredient
Dosage
200 mg
Dosage form Tablets
Tablets per pack 21

LuciRibo is an advanced targeted antineoplastic agent belonging to the selective cyclin-dependent kinase inhibitor class, indicated for the treatment of hormone-dependent breast cancer. The active pharmaceutical ingredient is ribociclib at a strength of 200 mg supplied as film-coated oral tablets (Ribociclib Tablets 200 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Ribociclib is an oral, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases play a key role in cell cycle regulation, driving the transition from the G1 phase into the synthesis (S) phase. Overexpression of CDK4/D and CDK6/D complexes is frequently observed in hormone receptor-positive (HR+) breast cancer, resulting in uncontrolled tumor cell proliferation. CDK4/6 inhibition by ribociclib induces G1 cell cycle arrest and tumor growth suppression. The drug is administered in combination with endocrine therapy (aromatase inhibitors or fulvestrant).

Supplied in a package containing 21 tablets of 200 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciRibo 200 mg:

  • ✅ Selective CDK4/6 Inhibition: High selectivity for key cell cycle regulators to halt tumor cell division.
  • ✅ Proven Overall Survival: Significant clinical outcome improvements when combined with endocrine therapy in HR+/HER2- metastatic breast cancer.
  • ✅ Convenient Cyclic Schedule: Administered for 3 weeks followed by 1 week off (28-day cycle).
  • ✅ Optimal Strength: 200 mg tablets enable flexible daily dose accumulation (standard 600 mg/day).
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Kisqali).

LuciRibo is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Ribociclib (as ribociclib succinate) — 200 mg (equivalent to 200 mg ribociclib).
  • Excipients: Microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, iron oxide black, iron oxide red, macrogol, talc.

Packaging and Presentation: Film-coated tablets, 200 mg strength. Each package contains 21 tablets along with prescribing information. Labeled with LuciRibo (Ribociclib Tablets 200 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Ribociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Cyclin D and CDK4/6 complexes phosphorylate the retinoblastoma protein (Rb), triggering the cell cycle and proliferation. Selective CDK4/6 inhibition by ribociclib prevents Rb phosphorylation, leading to G1 cell cycle arrest and reduced tumor cell multiplication. Acts synergistically with estrogen receptor blockers.

Pharmacokinetics:

  • Absorption: Following oral administration, ribociclib is absorbed; peak plasma concentration (Tmax) is achieved within approximately 1 to 4 hours. Food intake has no clinically significant effect on absorption.
  • Distribution: Human plasma protein binding is approximately 70%.
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 enzyme of the cytochrome P450 system.
  • Elimination: Excreted predominantly via feces (approx. 69%) and renally (approx. 23%). Terminal elimination half-life (T1/2) averages approximately 32.6 hours.

LuciRibo is indicated in adult female and male patients for:

  • Breast Cancer: Treatment of hormone receptor-positive (HR-positive), HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (e.g., letrozole) or fulvestrant as initial or subsequent line endocrine therapy.

LuciRibo is administered orally once daily for 3 consecutive weeks followed by a 1-week off period (forming a 28-day treatment cycle).

Dosing Regimen:
The recommended standard dose is 600 mg (three 200 mg tablets) once daily for 21 consecutive days followed by a 7-day rest period (21/7 schedule).

Administration Guidelines:
Tablets should be taken in the morning, at approximately the same time each day, regardless of food intake, with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, do not take an extra dose that day — take the next dose as scheduled the following day.

Administration of LuciRibo is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to ribociclib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction (requiring dosage adjustment if applicable).
  • QT Interval Prolongation: Baseline prominent QTc interval prolongation or predisposing risk factors for severe arrhythmias.

Ribociclib is metabolized primarily via CYP3A4:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly elevate ribociclib plasma concentrations and cardiotoxicity risks (avoid concurrent use).
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease ribociclib blood concentrations and reduce antitumor efficacy (avoid concurrent use).
  • QT-Prolonging Drugs: Co-administration with antiarrhythmics and other QT-prolonging agents is strictly discouraged.

Pregnancy:
LuciRibo is contraindicated during pregnancy. Based on its mechanism of action, ribociclib may cause fetal harm and embryotoxicity. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 3 weeks following the final dose.

Lactation:
Excretion of ribociclib into human breast milk cannot be ruled out. Breastfeeding must be discontinued during treatment and for at least 3 weeks post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Hematologic Toxicity: Neutropenia (a very common adverse event requiring regular complete blood count monitoring), leukopenia, anemia, thrombocytopenia.
  • Cardiovascular System: QT interval prolongation on electrocardiogram (ECG) (ECG and electrolyte monitoring required).
  • Gastrointestinal Tract: Nausea, diarrhea, vomiting, constipation, stomatitis, abdominal pain, decreased appetite.
  • Hepatic Abnormalities: Elevations in liver transaminases (ALT, AST) and bilirubin levels.
  • General Disorders: Fatigue, asthenia, alopecia, headache, rash.

Symptoms:
Specific acute overdose symptoms of ribociclib are unestablished. Anticipated manifestations include exacerbated adverse reactions (neutropenia, nausea, cardiotoxicity).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under medical observation.

Storage Requirements for LuciRibo 200 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciRibo 200 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Ribociclib Tablets 200 mg, and 21 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00